Insulin-like growth factor-1 stimulation of lymphopoiesis.
Open Access
- 1 August 1993
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 92 (2), 540-548
- https://doi.org/10.1172/jci116621
Abstract
We show that treatment of adult mice with recombinant human insulin-like growth factor 1 (rhIGF-1) induces striking modifications in lymphocyte number and function. 9-mo-old male mice received rhIGF-1 (4 mg/kg per d) or its excipient by subcutaneous infusion from osmotic minipumps for 7 or 14 d. Mice were weighed daily and bled at sacrifice; the spleen and thymus were harvested and single cell suspensions were made for analysis of cell phenotype and cell number. The responses of splenocytes to mitogens (concanavalin A, lipopolysaccharide, and pokeweed mitogen), alloantigens and dinitrophenyl ovalbumin were measured. After either 7 or 14 d of treatment, rhIGF-1 had an overall whole-body anabolic effect, resulting in increased body and organ weights with prominent increases in the weight of the spleen and thymus. Furthermore, the rhIGF-1 treated mice were normoglycemic but had reduced blood urea nitrogens, again reflecting the anabolic activity of rhIGF-1. The increased spleen and thymus weights were associated with a large increase in the number of lymphocytes in both organs. In addition to an increase in T cells, specifically CD4+ T cells, a dramatic increase in splenic B cells was also observed. This increase was accompanied by an enhanced responsiveness to dinitrophenyl ovalbumin resulting in increased immunoglobulin production. However, despite the increases in cellularity, there was a decrease in the in vitro responses of spleen cells to mitogens after 7 d of rhIGF-1 treatment. In contrast, treatment with rhIGF-1 for 14 d increased both the cell number and mitogenic responses of splenocytes suggesting that some time is required for the cells populating the peripheral organs to gain mitogenic responsiveness. It is clear from these data that rhIGF-1, at doses that have whole-body anabolic activity, can expand cell number in lymphoid tissue in a normal adult mouse. These dual effects of rhIGF-1, of increasing lymphocyte number and activity, indicate that, in a normal adult animal, rhIGF-1 can cause major changes in lymphoid tissues that are of potential benefit to the functioning of the immune system.This publication has 31 references indexed in Scilit:
- Role of neuroendocrine hormones in murine T cell development. Growth hormone exerts thymopoietic effects in vivo.The Journal of Immunology, 1992
- Repopulation of the atrophied thymus in diabetic rats by insulin-like growth factor I.Proceedings of the National Academy of Sciences, 1990
- Stimulation of Supranormal Growth in Prepubertal, Adult Plateaued, and Hypophysectomized Female Rats by Large Doses of Rat Growth Hormone: Physiological Effects and Adverse Consequences*Endocrinology, 1987
- Biosynthetic Somatomedin C (SM-C/IGF-I) Increases the Length and Weight of Snell Dwarf MicePediatric Research, 1986
- Ontogenic development of proliferative and polyclonal antibody and autoantibody responses to staphylococcal peptidoglycan, protein a and cell walls in miceDevelopmental & Comparative Immunology, 1985
- T-cell maturation in the human thymus and tonsil: Peanut agglutinin binding T lymphocytes in thymus and tonsil differ in maturation stageClinical Immunology and Immunopathology, 1983
- Effect of purified somatomedins on thymidine incorporation into lectin-activated human lymphocytesActa Endocrinologica, 1983
- EFFECT OF BOVINE GROWTH HORMONE AND A PARTIALLY PURE PREPARATION OF SOMATOMEDIN ON VARIOUS GROWTH PARAMETERS IN HYPOPITUITARY DWARF MICEJournal of Endocrinology, 1981
- Somatomedin: Proposed Designation for Sulphation FactorNature, 1972
- Hormones and the immunological capacity. 3. The immunodeficiency disease of the hypopituitary Snell-Bagg dwarf mouse.1971